Price alert —
Sign in to get a one-time email the moment VTRS crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · VTRS
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3.5B | $0.2B | $-0.0B | $0.3B | 5.0% | -0.6% |
| 2025-12-31 | $3.7B | $-0.3B | $-0.2B | $0.6B | -9.2% | -4.3% |
| 2025-09-30 | $3.8B | $-0.1B | $0.2B | $0.6B | -3.4% | 6.2% |
| 2025-06-30 | $3.6B | $-0.0B | $0.2B | $0.2B | -0.1% | 5.2% |
| 2025-03-31 | $3.3B | $-3.0B | $-0.0B | $0.5B | -93.5% | -0.3% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare VTRS vs peers
Line VTRS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with VTRS
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | 0.59 | 0.50 | +17.5% | -1.3% |
| 2026-02-26 | 0.57 | 0.53 | +7.4% | -2.1% |
| 2025-11-06 | 0.67 | 0.62 | +8.5% | +0.1% |
| 2025-08-07 | 0.62 | 0.56 | +11.6% | +3.3% |
| 2025-05-08 | 0.50 | 0.49 | +1.6% | -3.5% |
| 2025-02-27 | 0.54 | 0.57 | -5.6% | -3.1% |
| 2024-11-07 | 0.75 | 0.68 | +10.7% | -1.7% |
| 2024-08-08 | 0.69 | 0.68 | +2.3% | -2.6% |
| 2024-05-09 | 0.67 | 0.67 | -0.4% | -0.5% |
| 2024-02-28 | 0.62 | 0.65 | -4.3% | +0.7% |
| 2023-11-07 | 0.79 | 0.74 | +6.8% | +1.0% |
| 2023-08-07 | 0.75 | 0.71 | +5.4% | +1.4% |
| 2023-05-08 | 0.77 | 0.70 | +10.6% | -0.8% |
| 2023-02-27 | 0.67 | 0.72 | -6.1% | +1.8% |
| 2022-11-07 | 0.87 | 0.84 | +4.3% | +1.2% |
| 2022-08-08 | 0.88 | 0.82 | +7.1% | +3.7% |
| 2022-05-09 | 0.93 | 0.83 | +12.3% | -0.2% |
| 2022-02-28 | 0.80 | 0.83 | -3.0% | -7.8% |
| 2021-11-08 | 0.99 | 0.88 | +11.9% | -0.8% |
| 2021-08-09 | 0.98 | 0.88 | +11.1% | +0.1% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| VTRS ★ | $20B | — | 6.5 | 1.4 | 7.8 | 1.4 | 39.8% | 8.1% | — | 11.28% |
| LLY | — | 41.1 | 25.7 | — | 29.3 | — | 82.8% | 55.5% | 169.9% | — |
| UNH | $391B | 32.4 | 19.2 | 0.9 | 17.5 | 3.7 | 19.5% | 0.4% | 61.5% | 5.82% |
| JNJ | $600B | 28.9 | 19.4 | 6.1 | 18.1 | 7.4 | 68.1% | 6.6% | -1.0% | — |
| MRK | $312B | 35.6 | 13.1 | — | 11.9 | 6.8 | 76.7% | 4.9% | — | 4.50% |
| ABBV | $451B | 124.6 | 15.7 | 7.2 | 17.1 | -67.8 | 72.0% | 12.4% | -46.2% | 4.61% |
| PFE | $142B | 19.3 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.72% |
| TMO | — | 28.4 | 19.0 | — | 20.9 | — | 40.9% | 6.2% | 11.3% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 45.95%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 84,359,804 | 7.24% |
| Davis Selected Advisers | 78,211,191 | 6.72% |
| Vanguard Capital Management LLC | 74,716,631 | 6.42% |
| Price (T.Rowe) Associates Inc | 65,864,104 | 5.66% |
| Vanguard Portfolio Management LLC | 53,911,237 | 4.63% |
| State Street Corporation | 52,233,699 | 4.49% |
| Dimensional Fund Advisors LP | 38,310,693 | 3.29% |
| Rubric Capital Management LP | 33,500,000 | 2.88% |
| Geode Capital Management, LLC | 31,846,107 | 2.73% |
| Invesco Ltd. | 21,968,657 | 1.89% |
Insider activity · 90d
2 buys / 1 sells · ratio 2.0 · Finnhub
- Groothuis Leo Frans BUY 2,756 @ $15.88
- SIMMONS DAVID S BUY 2,362 @ $15.88
- Campbell Paul SELL 316,212 @ $16.17
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-01 | FORM 4 | view · |
| 4 | 2026-07-01 | FORM 4 | view · |
| 8-K | 2026-07-01 | 8-K | view · |
| 4 | 2026-06-26 | FORM 4 | view · |
| 8-K | 2026-06-18 | 8-K | view · |
| 8-K | 2026-06-15 | 8-K | view · |
| 8-K | 2026-05-15 | 8-K | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| 4 | 2026-04-16 | FORM 4 | view · |
| DEF 14A | 2026-04-02 | DEF 14A | view · |
| 4 | 2026-03-24 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 8-K | 2026-02-26 | 8-K | view · |
| 8-K | 2026-02-03 | 8-K | view · |
| 4 | 2026-01-02 | FORM 4 | view · |
| 8-K | 2025-12-08 | 8-K | view · |
| 8-K | 2025-12-05 | 8-K | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 8-K | 2025-11-06 | 8-K | view · |
| 8-K | 2025-10-24 | 8-K | view · |
| DEF 14A | 2025-10-24 | DEF 14A | view · |
| 4 | 2025-09-12 | FORM 4 | view · |
| 4 | 2025-08-19 | FORM 4 | view · |
| 4 | 2025-08-13 | FORM 4 | view · |
| 4 | 2025-08-13 | FORM 4 | view · |
| 10-Q | 2025-08-07 | 10-Q | view · |
| 8-K | 2025-08-07 | 8-K | view · |
| 8-K | 2025-08-05 | 8-K | view · |
| 4 | 2025-05-14 | FORM 4 | view · |
| 4 | 2025-05-13 | FORM 4 | view · |
| 4 | 2025-05-13 | FORM 4 | view · |
| 10-Q | 2025-05-08 | 10-Q | view · |
| 8-K | 2025-05-08 | 8-K | view · |
| 8-K | 2025-05-05 | 8-K | view · |
| 4 | 2025-04-16 | 4 | view · |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order…
Options picks · VTRS
ITM + OTM ideas from the latest scanLoading…
Congress trades · VTRS
STOCK Act disclosuresLoading…
SEC filings & insiders · VTRS
EDGAR · liveLoading…
Holders · VTRS
Institutions & insider activityLoading…